Qnovia, a pharmaceutical company who recently announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the RespiRx™ Nicotine Inhaler (QN-01), a prescription inhaled smoking cessation medicine, today announced it has raised $16 million in Series B funding.

Qnovia是一家制药公司，最近宣布美国食品和药物管理局（FDA）批准其研究性新药（IND）申请，用于处方吸入式戒烟药RespiRx尼古丁吸入器（QN-01），今天宣布已筹集了1600万美元的B系列资金。

The financing was led by Blue Ledge Capital, Evolution VC Partners, Vice Ventures and Gaingels.Qnovia is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. The company's drug delivery platform, the RespiRx™, is the first orientation-agnostic, portable vibrating mesh nebulizer that effectively operates in any position held by the patient.

融资由Blue Ledge Capital、Evolution VC Partners、Vice Ventures和Gaingels牵头。。该公司的药物输送平台RespiRx是第一个方向不可知的便携式振动网雾化器，可在患者持有的任何位置有效运行。

Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs. The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies..

Qnovia看到了利用其药物输送技术改善哮喘，COPD，疫苗输送，疼痛管理以及几种仿制药和选择性研究新药治疗的重大机会。该公司于2018年由马里奥·达内克（Mario Danek）创立，旨在建立尖端的药物输送平台，通过卓越的设备技术改善患者的预后。。